Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
Novel small molecule inhibitors of c-Met signaling; these small molecules selectively bind to c-Met and have an IC50 in the micromolar range. More
These cell lines (based on the widely used B16 murine melanoma cell line) were transduced with retroviral vectors encoding cDNA for either CXCR4 or CCR10 under control of a TET-dependent promoter. More
A method of transfecting isolated autologous T-Lymphocytes with endogenous cytokines, for example IL-7 and IL-15, to sustain an adoptive T-lymphocyte response without systemic toxicity. More
Methods and assays which may be used to diagnose and follow the progression of cancers associated with c-Met expression More
These analogs were found to be potent inhibitors of IGF-1-mediated cell signaling and cancer cell growth, providing more binding specificity with less likelihood of significant toxic effects. More
An alternative type of immunotherapy which involves the adoptive transfer of autologous natural killer (NK) cells More
This technology involves the generation of several novel mouse monoclonal antibodies against a sub-domain of an MITF fragment that is cleaved during cell death. More
The compositions and methods of administration described in this invention are based on indole carbazole, which causes terminal differentiation of tumor cells by exploiting a normal physiologic pathway. More
These compositions may represent potential anticancer therapeutics, stimulating NY ESO-1/CAG-3-specific T cells to elicit an anti-cancer immunogenic response and thereby eliminating or reducing the cancer. More
In our studies, the absence of toxicity to "normal" cells coupled to its effectiveness on a wide range of cancer cell types suggests that PrAg-L1/LF may represent a novel cancer therapeutic. More
Related Reports
Market Research Reports provided by reports.iptechex.com
Nov 2010 - 26 pages - $125
Dec 2010 - 19 pages - $99
Dec 2010 - 26 pages - $500
Aug 2009 - $15,200
Nov 2010 - 639 pages - $1,495
Apr 2011 - 42 pages - $500
Aug 2010 - $15,200
Aug 2011 - 42 pages - $500
Nov 2009 - 160 pages - $2,265
Jun 2011 - 34 pages - $125
Your selection
Browse By
- Industry sector
- Animal health
- Biotechnology
- Diagnostic
- Drug delivery
- Drug discovery
- Medical device
- Pharmaceutical
- Research tools
- Therapeutic target
- Basal cell carcinoma
- Melanoma
- Squamous cell carcinoma
- Development phase
- Early Stage
- Preclinical
- Phase I
- Phase I/II
- Phase II
- Phase III
- Phase III/IV
- Preregistration
- Registered
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us